R. McMenemin

发表

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer

C. Ponting, A. Heger, D. Sims, 2014, BMC Cancer.

A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.

N. O'Rourke, R. McMenemin, J. Paul, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I

M. Dempsey, R. McMenemin, N. Reed, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Muscular metastasis, a rare presentation of non-small-cell lung cancer.

A. Razak, R. McMenemin, S. England, 2007, MedGenMed : Medscape general medicine.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

F. McDonald, R. McMenemin, S. Singhal, 2020, Ecancermedicalscience.

Abnormal expression of growth regulatory factors in Barrett's oesophagus.

D. Hopwood, R. McMenemin, J. Jankowski, 1991, Clinical science.

The implementation of an advanced treatment planning algorithm in the treatment of lung cancer with conventional radiotherapy.

F. McDonald, R. McMenemin, P. Mulvenna, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

A. Bezjak, J. V. van Meerbeeck, C. Faivre-Finn, 2017, The Lancet. Oncology.

Guidelines for the diagnosis, prevention and management of chemical- and radiation-induced cystitis

R. Huddart, H. Payne, R. McMenemin, 2014 .

Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges

R. Huddart, H. Payne, R. McMenemin, 2013, BJU international.

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.

I. Pedley, R. McMenemin, R. Pearson, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC.

N. O'Rourke, R. McMenemin, C. Peedell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland

R. Huddart, L. Pickering, N. Elander, 2017, International journal of oncology.

Second-line chemotherapy for advanced bladder cancer: a survey of current UK practice.

N. Vasdev, H. Payne, B. Lamb, 2014, Urologic oncology.

Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro‐oncologists' opinions and practice

J. Staffurth, H. Payne, R. McMenemin, 2018, International journal of clinical practice.

Thyroid stunning after (131)I diagnostic whole-body scanning.

M. Dempsey, R. McMenemin, N. Reed, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Letters to the Editor Thyroid Stunning After 131 I Diagnostic Whole

M. Dempsey, R. McMenemin, N. Reed, 2001 .

CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016 .

Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression.

D. Hopwood, R. McMenemin, J. Jankowski, 1992, Gut.

Delays in the diagnosis and treatment of muscle invasive bladder cancer: A pilot project mapping the pathway

I. Pedley, R. Heer, R. Pickles, 2015 .

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

Andreas Heger, Chris P. Ponting, Owen J. Sansom, 2014, European urology.

Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.

James M. Wilson, P. Rajan, I. Pedley, 2015, Urologic oncology.

A Phase II Study of CaelyxTM (Liposomal Doxorubicin) in Metastatic Carcinoma of the Prostate: Tolerability and Efficacy Modification by Liposomal Encapsulation

D. Bissett, R. McMenemin, L. Moffat, 2002, Investigational New Drugs.

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.

E. Frangou, M. Stockler, M. Parmar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.

N. O'Rourke, R. McMenemin, C. Peedell, 2014, European journal of cancer.

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.

K. Hopkins, A. Hackshaw, N. O'Rourke, 2019, JAMA.

Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study

Tufve Nyholm, Per Bergström, Joakim Jonsson, 2013, Radiation oncology.

Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.

A. Hackshaw, N. O'Rourke, P. Hoskin, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review.

F. McDonald, R. McMenemin, A. Greystoke, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup

V. Khoo, K. Muir, P. Sooriakumaran, 2016 .

18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial

C. Faivre-Finn, I. Locke, P. Julyan, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy for bladder cancer: an update

Carys W Thomas, H. Payne, B. Lamb, 2012 .

Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study.

I. Pedley, N. Soomro, H. Leung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA13.01 The Impact of [18F]fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial

C. Faivre-Finn, I. Locke, P. Julyan, 2018, Journal of Thoracic Oncology.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

P-419 A randomised controlled trial of radiotherapy to mesotheliomadrain sites

N. O'Rourke, R. McMenemin, C. Lawless, 2005 .

An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced/metastatic hormone sensitive prostate cancer.

I. Pedley, R. McMenemin, A. Azzabi, 2017 .